[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550272":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":45,"responsibleParty":97,"collaborators":99,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":105,"sex":111,"minAge":112,"maxAge":43,"enrollmentInfo":113,"targetDuration":43,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":43,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Capsaicin 8%","EXPERIMENTAL","patch 179 mg, 30 min",[13],"Drug: Capsaicin 179 Mg Cutaneous Patch",{"label":15,"type":16,"description":17,"interventionNames":18},"Capsaicin 0.04%","SHAM_COMPARATOR","patch low dose, 30 min",[19],"Drug: Capsaicine low dose 0.04 %",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Capsaicin 179 Mg Cutaneous Patch","patch application for 30 minutes on the painful fingers.",[9],[27],"QUTENZA",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Capsaicine low dose 0.04 %","patch application for 30 minutes on the painful fingers. the low-dose patch has a similar appearance to the active patch. It allows you to keep the blind, because it also causes reactions at the capsaicin application site (erythema, burning).",[15],[33],"control treatment",[35],{"name":36,"affiliation":5,"role":37},"Sylvain Mathieu","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Lise Laclautre","CONTACT","334.73.754.963",null,"promo_interne_drci@chu-clermontferrand.fr",[46,61,73,85],{"facility":47,"status":48,"city":49,"state":43,"zip":43,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"CHU de Clermont-Ferrand","RECRUITING","Clermont-Ferrand","France","FR",{"type":53,"coordinates":54},"Point",[55,56],3.08682,45.77969,{"lat":56,"lon":55},[59,60],{"name":40,"role":41,"phone":43,"phoneExt":43,"email":43},{"name":36,"role":37,"phone":43,"phoneExt":43,"email":43},{"facility":62,"status":48,"city":63,"state":43,"zip":43,"country":50,"countryCode":51,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"HCL Hôpital Edouard Herriot","Lyon",{"type":53,"coordinates":65},[66,67],4.84789,45.74906,{"lat":67,"lon":66},[70,71],{"name":40,"role":41,"phone":43,"phoneExt":43,"email":43},{"name":72,"role":37,"phone":43,"phoneExt":43,"email":43},"Roland CHAPURLAT",{"facility":74,"status":48,"city":75,"state":43,"zip":43,"country":50,"countryCode":51,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"AP-HP Hôpital Saint-Antoine","Paris",{"type":53,"coordinates":77},[78,79],2.3488,48.85341,{"lat":79,"lon":78},[82,83],{"name":40,"role":41,"phone":43,"phoneExt":43,"email":43},{"name":84,"role":37,"phone":43,"phoneExt":43,"email":43},"Jérémie SELLAM",{"facility":86,"status":48,"city":87,"state":43,"zip":43,"country":50,"countryCode":51,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"CHU de Saint-Etienne","Saint-Etienne",{"type":53,"coordinates":89},[90,91],4.39,45.43389,{"lat":91,"lon":90},[94,95],{"name":40,"role":41,"phone":43,"phoneExt":43,"email":43},{"name":96,"role":37,"phone":43,"phoneExt":43,"email":43},"Thierry Thomas",{"type":98,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR",[100],{"name":101,"class":102},"Grünenthal GmbH","INDUSTRY","100550272","phase-4-capsaicin-in-digital-osteoarthritis-versus-control-100550272",false,"NCT06444919","Capsaicin in Digital Osteoarthritis Versus Control","Capsaicin in Digital Osteoarthritis Versus Control : a Randomized Study","CADOR","Inclusion Criteria:\n\n* Diagnosis of digital osteoarthritis fulfilling the American College of Rheumatology criteria;\n* Presence of finger pain of ≥ 40 mm on a visual analogue scale (VAS);\n* Presence of finger pain with a neuropathic pain component (DN4 score ≥ 4\u002F10)\n* Inadequate response, adverse reactions, and\u002For contraindications to conventional analgesics and NSAIDs;\n\nExclusion Criteria:\n\n* Patient with isolated rhizarthrosis;\n* Patient with other joint disease affecting the fingers (gout, chondrocalcinosis, RA, spondyloarthritis, psoriatic arthritis);\n* Patient with upper extremity pain syndrome that may interfere with the assessment of finger pain;\n* Patient with another pathology responsible for neuropathic hand pain (carpal tunnel syndrome, diabetic neuropathy, Guyon's tunnel syndrome, cervicobrachial neuralgia, brachial plexitis);\n* Patient with skin lesions on the fingers (psoriasis, wounds, chronic ulcers, eczema, shingles, dermatitis);\n* Patient with poorly controlled high blood pressure;\n* Patient with hypersensitivity to capsaicin;\n* Patient who had 8% capsaicin patch use in the year prior to the study;\n* Patient who has received intramuscular, intra-articular or intravenous corticosteroid therapy, another disease-modifying anti-rheumatic therapy (methotrexate, salazopyrine) or an intra-articular injection into the joints of the fingers within the previous 3 months;\n* Patient wearing wrist or finger orthoses in the previous month;\n* Patient with fibromyalgia;","ALL","18 Years",{"count":114,"type":115},120,"ESTIMATED","INTERVENTIONAL",[118],"PHASE4","The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component.\n\nParticipants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%).\n\nResearchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)",[121,122],"Osteoarthritis Hand","Neuropathic Pain","2025-03-12",{"date":125,"type":126},"2025-03-13","ACTUAL",{"date":128,"type":115},"2025-03-07",{"date":130,"type":115},"2028-01-01",{"name":5,"class":6},4]